360 related articles for article (PubMed ID: 31306396)
1. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
Bradley JS; Broadhurst H; Cheng K; Mendez M; Newell P; Prchlik M; Stone GG; Talley AK; Tawadrous M; Wajsbrot D; Yates K; Zuzova A; Gardner A
Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
Qin X; Tran BG; Kim MJ; Wang L; Nguyen DA; Chen Q; Song J; Laud PJ; Stone GG; Chow JW
Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
Lucasti C; Popescu I; Ramesh MK; Lipka J; Sable C
J Antimicrob Chemother; 2013 May; 68(5):1183-92. PubMed ID: 23391714
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Mazuski JE; Gasink LB; Armstrong J; Broadhurst H; Stone GG; Rank D; Llorens L; Newell P; Pachl J
Clin Infect Dis; 2016 Jun; 62(11):1380-1389. PubMed ID: 26962078
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial.
Bradley JS; Roilides E; Broadhurst H; Cheng K; Huang LM; MasCasullo V; Newell P; Stone GG; Tawadrous M; Wajsbrot D; Yates K; Gardner A
Pediatr Infect Dis J; 2019 Sep; 38(9):920-928. PubMed ID: 31335570
[TBL] [Abstract][Full Text] [Related]
6. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
Cheng K; Newell P; Chow JW; Broadhurst H; Wilson D; Yates K; Wardman A
Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
Buckman SA; Krekel T; Muller AE; Mazuski JE
Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
[TBL] [Abstract][Full Text] [Related]
10. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
11. Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets.
Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348155
[TBL] [Abstract][Full Text] [Related]
12. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
14. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
Chahine EB; Sourial M; Ortiz R
Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Franzese RC; McFadyen L; Watson KJ; Riccobene T; Carrothers TJ; Vourvahis M; Chan PLS; Raber S; Bradley JS; Lovern M
Clin Pharmacol Ther; 2022 Mar; 111(3):635-645. PubMed ID: 34687548
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
Torres A; Wible M; Tawadrous M; Irani P; Stone GG; Quintana A; Debabov D; Burroughs M; Bradford PA; Kollef M
J Antimicrob Chemother; 2023 Nov; 78(11):2672-2682. PubMed ID: 37700689
[TBL] [Abstract][Full Text] [Related]
18.
Stone GG; Newell P; Bradford PA
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686147
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
